{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:57:02Z","timestamp":1791100622655,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Chlorofluorocarbons (CFCs) have been implicated in damage to the ozone layer, and are due to be phased out in accordance with the Montreal Protocol.<\/jats:p><jats:p>\u2022\u2003Hydrofluoroalkane\u2010134a (HFA) has been found to act as an adequate propellant for pressurized metered\u2010dose inhaler delivery systems without the same deleterious environmental effects.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003This paper presents data from both steady\u2010state pharmacokinetic and pharmacodynamic assessments of HFA<jats:italic>vs.<\/jats:italic>CFC pressurized metered\u2010dose inhaler formulations of budesonide. It demonstrates that they are therapeutically equivalent in terms of relative lung bioavailability, airway efficacy and systemic effects.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold>A hydrofluoroalkane formulation of budesonide pressurized metered\u2010dose inhaler has been developed to replace the existing chlorofluorocarbon one. The aim of this study was to evaluate the pharmacokinetic and pharmacodynamic characteristics of both formulations.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold>Systemic bioavailability and bioactivity of both hydrofluoroalkane and chlorofluorocarbon pressurized metered\u2010dose inhaler formulations at 800\u2003\u00b5g twice daily was determined during a randomized crossover systemic pharmacokinetic\/pharmacodynamic study at steady state in healthy volunteers. Measurements included the following: plasma cortisol AUC<jats:sub>24h<\/jats:sub>[area under the concentration\u2010time curve (0\u201324\u2003h)], budesonide AUC<jats:sub>0\u201312h<\/jats:sub>and<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>. Clinical efficacy was determined during a randomized crossover pharmacodynamic study in asthmatic patients receiving 200\u2003\u00b5g followed by 800\u2003\u00b5g budesonide via chlorofluorocarbon or hydrofluoroalkane pressurized metered\u2010dose inhaler each for 4 weeks. Methacholine PC<jats:sub>20<\/jats:sub>(primary outcome), exhaled nitric oxide, spirometry, peak expiratory flow and symptoms were evaluated.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>In the pharmacokinetic study, there were no differences in cortisol, AUC<jats:sub>0\u201312h<\/jats:sub>[area under the concentration\u2010time curve (0\u201312\u2003h)],<jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub>(time to maximum concentration) or<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>(peak serum concentration) between the hydrofluoroalkane and chlorofluorocarbon pressurized metered\u2010dose inhaler. The ratio of budesonide hydrofluoroalkane<jats:italic>vs.<\/jats:italic>chlorofluorocarbon pressurized metered\u2010dose inhaler for cortisol AUC<jats:sub>24h<\/jats:sub>was 1.02 (95% confidence interval 0.93\u20131.11) and budesonide AUC<jats:sub>0\u201312h<\/jats:sub>was 1.03 (90% confidence interval 0.9\u20131.18). In the asthma pharmacodynamic study, there was a significant dose response (<jats:italic>P<\/jats:italic>&lt; 0.0001) for methacholine PC<jats:sub>20<\/jats:sub>(provocative concentration of methacholine needed to produce a 20% fall in FEV<jats:sub>1<\/jats:sub>) with a relative potency ratio of 1.10 (95% confidence interval 0.49\u20132.66), and no difference at either dose. No significant differences between formulations were seen with the secondary outcome variables.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold>Hydrofluoroalkane and chlorofluorocarbon formulations of budesonide were therapeutically equivalent in terms of relative lung bioavailability, airway efficacy and systemic effects.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03857.x","type":"journal-article","created":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T10:18:56Z","timestamp":1289989136000},"page":"504-513","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide"],"prefix":"10.1111","volume":"71","author":[{"given":"Karine L.","family":"Clearie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter. A.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Meldrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars\u2010Goran","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Carlholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ekelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.6.9805093"},{"issue":"4","key":"e_1_2_7_3_2","article-title":"Inhaled short acting beta2\u2010agonist use in asthma: regular vs as needed treatment","author":"Walters EH","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_4_2","first-page":"56276","article-title":"The Montreal Protocol on substances that deplete the ozone layer. Final act (Nairobi: UNEP, 1987)","volume":"59","year":"1994","journal-title":"Federal Register"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-500OC"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.ats11-99"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.2517-6161.1954.tb00159.x","article-title":"Some problems in interval estimation","volume":"16","author":"Fieller EC","year":"1954","journal-title":"J R Stat Soc B Stat Methodol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61327-0"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.6.9703003"},{"key":"e_1_2_7_10_2","unstructured":"EMEA.2009.Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatemnt of asthma and chronic obstructive pulmonary disease (COPD) in adults and for the use in the treatment of asthma in children and adolescents. Available athttp:\/\/www.emea.europa.eu\/pdfs\/human\/ewp\/4850108en.pdf(last accessed 11 September 2009)."},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14a12.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.4.9806052"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02365.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.6.500"},{"key":"e_1_2_7_15_2","article-title":"Steroid sparing effects of intranasal corticosteroids in asthma and allergic rhinitis","author":"Nair A","year":"2009","journal-title":"Allergy"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70016-3"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.103"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.109622"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.2.91"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60909-X"},{"key":"e_1_2_7_21_2","first-page":"16","article-title":"Clinical dose\u2010response relationship of fluticasone propionate in adults with asthma","volume":"59","author":"Masoli M","year":"2004","journal-title":"Thorax"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62914-6"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.1.20"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03857.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03857.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T21:59:56Z","timestamp":1740693596000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03857.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03857.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03857.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}